Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

PACB

Live52w low +31.6%

Annual Quarterly

Core line items from PACB's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Pacific Biosciences of California, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$42.64M	$37.18M	$115.36M	$76.92M	$37.15M
Operating Income	Not available	$-8.36M	$-512.66M	$-473.79M	$-428.93M
Net Income	Not available	$-8.28M	$-506.00M	$-468.00M	$-426.07M
EPS (Diluted)	$-0.13	$-0.03	$-1.69	$-1.57	$-1.44
Total Assets	Not available	$782.37M	$803.16M	$825.47M	$860.79M
Total Liabilities	Not available	$780.00M	$767.07M	$763.98M	$769.15M
Cash & Equivalents	Not available	$56.27M	$56.47M	$54.80M	$58.51M
Free Cash Flow OCF − CapEx	Not available	$-47.73M	$-93.99M	$-75.37M	$-45.45M
Shares Outstanding	Not available	310.49M	301.85M	300.35M	300.04M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from PACB's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +31.6%

Entity: Pacific Biosciences of California, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$42.64M	$37.18M	$115.36M	$76.92M	$37.15M
Operating Income	Not available	$-8.36M	$-512.66M	$-473.79M	$-428.93M
Net Income	Not available	$-8.28M	$-506.00M	$-468.00M	$-426.07M
EPS (Diluted)	$-0.13	$-0.03	$-1.69	$-1.57	$-1.44
Total Assets	Not available	$782.37M	$803.16M	$825.47M	$860.79M
Total Liabilities	Not available	$780.00M	$767.07M	$763.98M	$769.15M
Cash & Equivalents	Not available	$56.27M	$56.47M	$54.80M	$58.51M
Free Cash Flow OCF − CapEx	Not available	$-47.73M	$-93.99M	$-75.37M	$-45.45M
Shares Outstanding	Not available	310.49M	301.85M	300.35M	300.04M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.